Enhanced Recovery After Surgery (ERAS) in Surgical Oncology
Purpose of the Review The objective of this review is to address the rationale behind the application of the Enhanced Recovery After Surgery (ERAS) protocols that could improve oncologic outcomes in adult patients undergoing major surgery. Recent Findings The implementation of ERAS protocols has been associated with fewer postoperative complications as well as decreased return to intended oncologic treatment (RIOT). However, few studies have analyzed the influence of the application of ERAS protocols and long-term oncologic outcomes, although some of its individual elements have been associated with improvements in oncologic outcomes, including overall survival and disease-free survival. Summary Targeted long-term follow-up studies in specific oncologic procedures are required to determine whether ERAS application results in improved oncologic outcomes..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
---|---|
Enthalten in: |
Current oncology reports - 24(2022), 9 vom: 11. Apr., Seite 1177-1187 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ripollés-Melchor, Javier [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Anmerkungen: |
© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 |
---|
doi: |
10.1007/s11912-022-01282-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR048079685 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR048079685 | ||
003 | DE-627 | ||
005 | 20230519100254.0 | ||
007 | cr uuu---uuuuu | ||
008 | 220913s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s11912-022-01282-4 |2 doi | |
035 | |a (DE-627)SPR048079685 | ||
035 | |a (SPR)s11912-022-01282-4-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ripollés-Melchor, Javier |e verfasserin |4 aut | |
245 | 1 | 0 | |a Enhanced Recovery After Surgery (ERAS) in Surgical Oncology |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022 | ||
520 | |a Purpose of the Review The objective of this review is to address the rationale behind the application of the Enhanced Recovery After Surgery (ERAS) protocols that could improve oncologic outcomes in adult patients undergoing major surgery. Recent Findings The implementation of ERAS protocols has been associated with fewer postoperative complications as well as decreased return to intended oncologic treatment (RIOT). However, few studies have analyzed the influence of the application of ERAS protocols and long-term oncologic outcomes, although some of its individual elements have been associated with improvements in oncologic outcomes, including overall survival and disease-free survival. Summary Targeted long-term follow-up studies in specific oncologic procedures are required to determine whether ERAS application results in improved oncologic outcomes. | ||
650 | 4 | |a Adenocarcinoma/surgery |7 (dpeaa)DE-He213 | |
650 | 4 | |a Colonic neoplasms/pathology |7 (dpeaa)DE-He213 | |
650 | 4 | |a Colonic neoplasms/surgery |7 (dpeaa)DE-He213 | |
650 | 4 | |a Laparoscopy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neoplasm staging |7 (dpeaa)DE-He213 | |
650 | 4 | |a Survival analysis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Treatment outcome |7 (dpeaa)DE-He213 | |
650 | 4 | |a Analgesia*/mortality |7 (dpeaa)DE-He213 | |
650 | 4 | |a Anesthesia, conduction/adverse effects |7 (dpeaa)DE-He213 | |
650 | 4 | |a Disease progression |7 (dpeaa)DE-He213 | |
650 | 4 | |a Disease-free survival |7 (dpeaa)DE-He213 | |
650 | 4 | |a Humans |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neoplasm recurrence, local/mortality |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neoplasm recurrence, local/prevention and control |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neoplasms/immunology |7 (dpeaa)DE-He213 | |
650 | 4 | |a Neoplasms/mortality |7 (dpeaa)DE-He213 | |
700 | 1 | |a Abad-Motos, Ane |4 aut | |
700 | 1 | |a Zorrilla-Vaca, Andrés |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d Philadelphia, Pa. : Current Science, Inc., 1999 |g 24(2022), 9 vom: 11. Apr., Seite 1177-1187 |w (DE-627)SPR022982957 |w (DE-600)2054295-1 |x 1534-6269 |7 nnns |
773 | 1 | 8 | |g volume:24 |g year:2022 |g number:9 |g day:11 |g month:04 |g pages:1177-1187 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s11912-022-01282-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 24 |j 2022 |e 9 |b 11 |c 04 |h 1177-1187 |